Patents
Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210)
08/2004
08/05/2004WO2004064773A2 Inhibition of e3-ubiquitin ligase hakai for treatment of proliferative disorders
08/05/2004WO2004064768A2 Animal model for alzheimer's disease
08/05/2004WO2004064765A2 Herpesvirus amplicon particles
08/05/2004WO2004064760A2 Aptamer therapeutics useful in ocular pharmacotherapy
08/05/2004WO2004064744A2 Methods for site-directed mutagenesis and targeted randomization
08/05/2004WO2004064737A2 Therapeutics compositions
08/05/2004WO2004064714A2 Animal model for obesity independently of insulin resistance
08/05/2004WO2004064711A2 Modulation of deubiquitinase family members
08/05/2004WO2004064501A2 Transgenic animals expressing transdominant negative retroviral nucleic acids and proteins
08/05/2004WO2004064500A2 Transcriptional coactivator asc-2
08/05/2004WO2004055183A3 Carcinoembryonic antigen-specific immunodominant epitope recognized by cd4+t cells and uses thereof
08/05/2004WO2004053160A3 Method to analyze polymeric nucleic acid sequence variations
08/05/2004WO2004052928A3 Midkine-like protein
08/05/2004WO2004044195A3 Polynucleotides encoding agmatine coumaroyltransferase (act) and uses thereof
08/05/2004WO2004043996A3 Ligands
08/05/2004WO2004039987A3 Methods for increasing the efficiency of homologous recombination in cells of vascular plants
08/05/2004WO2004037976A3 NONSENSE-MEDIATED mRNA DECAY
08/05/2004WO2004033486A3 Production of homotrimeric fusion proteins
08/05/2004WO2004031242A3 Protein complexes involved in neurological diseases
08/05/2004WO2004028243A3 Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
08/05/2004WO2004027019A3 Improved raav expression systems for genetic modification of specific capsid proteins
08/05/2004WO2004024875A3 Mammalian megakaryocyte progenitor cell
08/05/2004WO2004024283A3 Apparatus and method for preparative scale purification of nucleic acids
08/05/2004WO2004024077A9 Novel composition and methods for the treatment of psoriasis
08/05/2004WO2004022716A9 Recombinatant mutants of rhabdovirus and methods of use thereof
08/05/2004WO2004020642A3 Stress tolerance and delayed senescence in plants
08/05/2004WO2004020465A3 Proteins involved in the regulation of energy homeostasis
08/05/2004WO2004019864A3 Quantitative rt-pcr to ac133 to diagnose cancer and monitor angiogenic activity in a cell sample
08/05/2004WO2004011938A3 Method and device for screening molecules in cells
08/05/2004WO2004009615A3 Cd40-ligand lacking native-pattern glycosylation
08/05/2004WO2004002214A3 Tagetes erecta marigolds with altered carotenoid compositions and ratios
08/05/2004WO2003104393A3 Three dimensional vaginal tissue model containing immune cells
08/05/2004WO2003104392A3 Improved reagents and methods for producing parvoviruses
08/05/2004WO2003102173A8 Protein or peptide (mimpd), nucleic acid that codes therefor, and uses of these substances
08/05/2004WO2003100011A3 Generation of histocompatible tissues using nuclear transplantation
08/05/2004WO2003085115A3 Identification and validation of novel targets for agrochemicals
08/05/2004WO2003063581A3 Compositions and methods for increasing animal size and growth rate
08/05/2004WO2003060093A3 METHODS AND COMPOSITIONS FOR PROPAGATING VECTORS CONTAINING TOXIC cDNAs AND ION CHANNEL ASSAY SYSTEMS
08/05/2004WO2003057899A3 Ion transporter stress-related polypeptides and methods of use in plants
08/05/2004WO2003057842A3 Aggrecanase molecules
08/05/2004WO2003057830A3 Compositions and methods for hydroxylating epothilones
08/05/2004WO2003054550A8 Uses of an endothelial cell receptor
08/05/2004WO2003048383A3 Effectors of innate immunity
08/05/2004WO2003042359A3 Histamine receptor h3 polynucleotides
08/05/2004WO2003040321A3 Antisense modulation of eif2c1 expression
08/05/2004WO2003039462A3 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
08/05/2004WO2003038049A3 Method for isolating cell-type specific mrnas
08/05/2004WO2003029411A3 Novel cyclooxygenase variants and methods of use
08/05/2004WO2003022227A3 Antisense modulation of vascular endothelial growth factor receptor-1 expression
08/05/2004WO2003015768A3 Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
08/05/2004WO2003012063A3 Polynucleotide encoding a novel trp channel family member, ltrpc3, and splice variants thereof
08/05/2004WO2003000038A9 Compositions and methods for modulating plant development
08/05/2004WO2002102976A3 Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
08/05/2004WO2002101357A3 Molecular signatures of commonly fatal carcinomas
08/05/2004WO2002090552A3 Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
08/05/2004WO2002090517A3 Novel human kinases and polynucleotides encoding the same
08/05/2004WO2002074926A3 Myo-inositol oxygenases
08/05/2004WO2002055548A3 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
08/05/2004US20040154056 Novel molecules of the multi-drug and toxin efflux (MATE) protein family and uses thereof
08/05/2004US20040154055 Theobromine synthase polypeptide of coffee plant and the gene encoding said polypeptide
08/05/2004US20040154054 Methods and compositions to reduce or eliminate transmission of a transgene
08/05/2004US20040154053 Signal transduction protein involved in plant dehiscence
08/05/2004US20040154052 Genetically engineering tobacco to express enzymes which convert sucrose/fructose into oligosaccharides; for use as sugar substitues in foods and in generating bifidogenic activity in animal feeds
08/05/2004US20040154051 Inducible promoters
08/05/2004US20040154049 Compounds
08/05/2004US20040154048 Activating nuclear transfered embryos via elevating cellular calcium levels and exposure to maturation promoting factor (MPF) inhibitor; artificial insemination and cloning; tissue engineering
08/05/2004US20040154047 Rodent animal model for use in identifying modulators for treatment of familial alzheimer's disease; targeted gene therapy
08/05/2004US20040154046 Gfp expression vector localized in mitochondria
08/05/2004US20040154045 Production of human recombinant collagen in the milk of transgenic animals
08/05/2004US20040154044 Transgenic cell and animal modeling ige-mediated human allergic responses and use thereof
08/05/2004US20040153255 Apparatus and method for encoding DNA sequence, and computer readable medium
08/05/2004US20040153254 Method for the efficiency-corrected real-time quantification of nucleic acids
08/05/2004US20040152879 Comprises receptor protein associated with osteocyte differentiation for identification of modulators associated with treatment bone and tumor disorders
08/05/2004US20040152878 Immunoglobulin which binds alpha helix cytokine for detection of wound healing and cell proliferative agents
08/05/2004US20040152876 Immunogenic HBc chimer particles having enhanced stability
08/05/2004US20040152875 Novel purinergic receptor
08/05/2004US20040152873 Novel gene bn01 mapping to chromosone 16q24.3
08/05/2004US20040152872 by using pairs of side chains to stabilize or to form pH-dependent molecular switches; genetic engineering
08/05/2004US20040152871 Comprises nucleotide sequences coding synoviolin polypeptide for identifying modulators for treatment of arthritic and inflammatory disorders
08/05/2004US20040152770 Highly-packed polycationic ammonium, sulfonium and phosphonium lipids
08/05/2004US20040152658 For therapy of animal having a deficiency in a neuron's immediate early gene responsiveness to a stimulus
08/05/2004US20040152655 Antisense oligonucleotides that inhibit expression of HIF-1
08/05/2004US20040152654 Inhibitory oligonucleotides targeted to Bcl-2
08/05/2004US20040152653 Administering a pharmacologic complex to the airway epithelium via its luminal surface, wherein the complex comprises a ligand for serpin enzyme complex receptor (SecR) and a pharmacologic agent
08/05/2004US20040152652 Therapy of inflammatory disorder in an individual comprising administering oligonucleotide up to 30 nucleotides in length complementary to a nucleic acid molecule encoding human tumor necrosis factor- alpha
08/05/2004US20040152651 Regulation of transcription elongation factors
08/05/2004US20040152647 For use in gene therapy
08/05/2004US20040152638 Protegrins
08/05/2004US20040152637 To assess the risk of individuals to suffer from vascular contraction of coronary arteries in mammals; for therapy of vascular contraction of coronary arteries
08/05/2004US20040152636 For therapy of diseases or disorders characterized by undesirable excessive vascularization such as tumors, rheumatoid arthritis, psoriasis, atherosclerosis, diabetic and other retinopathies, retrolental fibroplasia, macular degeneration
08/05/2004US20040152628 Platelet membrane glycoprotein VI (GPVI) DNA and protein sequences, and uses thereof
08/05/2004US20040152626 Identification of novel splice variants of the human catalytic subunit cbeta of camp-dependent protein kinase and the use thereof
08/05/2004US20040152197 Increasing agrobacterium transformation frequencies in maize via propagation in cysteine broth and histone expression
08/05/2004US20040152195 Vector for introducing molecules in eukaryotic cells and molecules vectorised by same
08/05/2004US20040152189 Transgenic embryonic progenitor cell which comprises nucleotide sequences coding octamer binding transcription factor 4 (OCT-4) promoter and a galactosyltransferase for use in tissue targeted therapy, drug screening and regeneration medicine
08/05/2004US20040152184 Transgenic escherichia comprising F' particle and enhanced gene transfer efficieny for use as diagnostic and prognostic tools in gene transfer protocal; bioreactors
08/05/2004US20040152183 Isolating infectious and non-infectious adenoviral or adenoassociated vector particles using chromatographic matrix; gene transfer tools and genetic engineering
08/05/2004US20040152182 Viral particles released after infection by human cytomegalovirus, and their use as vaccine
08/05/2004US20040152181 In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
08/05/2004US20040152174 Genetically modified eschrichia strain which is capable of biocoversion a single cacrbon source into 1, 3 propanediol using fermentation; bioreactors